SCHEMBL6422161

SCHEMBL6422161

Cc1ccccc1Nc1nc2nonc2nc1N/N=C/c1cccc2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
TP53 P04637 2/20 0.51
LMNA P02545 3/20 0.49
HTT P42858 1/20 0.49
BIRC5 O15392 1/20 0.47
KMT2A Q03164 7/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 6/20 0.39
HPGD P15428 1/20 0.39
CDKN1A P38936 1/20 0.39
GAA P10253 4/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
TDP1 Q9NUW8 1/20 0.39
LRRK2 Q5S007 1/20 0.39
POLB P06746 1/20 0.39
MGAM O43451 1/20 0.39
SI P14410 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6422164 1.00 MAPT (0.51) MAPTSMN1; SMN2TP53LMNAHTT
SCHEMBL26030540 1.00 MAPT (0.51) MAPTSMN1; SMN2TP53LMNAHTT
SCHEMBL6432648 0.83 KDM4E (0.48) MAPTSMN1; SMN2TP53LMNABIRC5
SCHEMBL6432652 0.83 KDM4E (0.48) MAPTSMN1; SMN2TP53LMNABIRC5
SCHEMBL6439892 0.78 KMT2A (0.51) MAPTSMN1; SMN2TP53LMNAHTT
SCHEMBL13310238 0.78 KMT2A (0.51) MAPTSMN1; SMN2TP53LMNAHTT
SCHEMBL6419812 0.78 MAPT (0.58) MAPTSMN1; SMN2TP53KMT2AKDM4E
SCHEMBL6419810 0.78 MAPT (0.58) MAPTSMN1; SMN2TP53KMT2AKDM4E
SCHEMBL20570269 0.78 TP53 (0.67) MAPTSMN1; SMN2TP53LMNAHTT
SCHEMBL13905878 0.76 BIRC5 (0.52) MAPTSMN1; SMN2TP53LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445677-B2 Substituted pyrimidyl guanidine derivatives having anticancer activity UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2013-05-21 US disclosed
US-8445677-B2 Substituted pyrimidyl guanidine derivatives having anticancer activity UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2013-05-21 US disclosed
US-20100160313-A1 DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2010-06-24 US disclosed
US-20100160313-A1 DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2010-06-24 US disclosed
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160313-A1 DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE ABCG2, NQO2, TOP1 MAPT 4028/4885SMN1; SMN2 4511/4885TP53 93/4885
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885SMN1; SMN2 4369/4885TP53 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.